NEW YORK (GenomeWeb News) – GenMark Diagnostics today said it has been granted a non-exclusive license to PerkinElmer's microfluidics patent portfolio.
Financial and other terms of the deal were not disclosed.
GenMark President and CEO Hany Massarany said in a statement, "Completing this agreement strengthens GenMark's patent portfolio and provides us with maximum flexibility as we expand our menu of high-value multiplex molecular tests."
PerkinElmer fortified its microfluidics portfolio with the $600 million acquisition of Caliper Life Sciences in November.
"The use of microfluidics for multiplexed molecular testing is a key enabling platform for personalized health research," Kevin Hrusovsky, president of Life Sciences and Technology for PerkinElmer, said. "We continue to leverage our expansive microfluidics portfolio, through non-exclusive licensing such as the one with GenMark, to extend our market reach and create revenue opportunities in applications and markets that complement our direct channel product offerings."